Chronic inflammation poses something of a mystery for researchers. If we become infected, the body immediately takes steps to repair and tidy it up. This process manifests itself as inflammation, which stems from a high level of activity in the immune cells, the body’s defence against bacteria and viruses.
The healthy blood cells stem from the blood bank at Rigshospitalet in Copenhagen, and more than 50 donors have been examined with the same result. Photo: Blood cells, Bruce Wetzel, Harry Schaefer, National Cancer Institute.
“Through analysing blood cells, we have observed that a particular protein called TL1A can get healthy cells to behave like those we see in chronic inflammation. This is bringing us closer to unlocking the mystery of inflammation,” says Kirsten Reichwald, PhD student at the Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen. The results have been published in PLOS ONE.
Biological treatment fights arthritis
Today, doctors can use so-called biological medicines for treating arthritis, which has radically changed the outlook for patients. Biological treatment works by impeding the harmful substances that are partly responsible for advancing the chronic inflammation in the body. Almost 40 per cent of arthritis patients experience a positive effect when taking biological medicines.
“Existing biological treatment means that doctors today can halt the diseases instead of just relieving the symptoms,” explains Kirsten Reichwald.
However, in order to block the right substances, doctors need detailed information about the processes that cause chronic inflammation. The researchers therefore studied cells from 50 blood donors from the blood bank at Rigshospitalet in Copenhagen, and concluded that the protein TL1A has a key role in the development of the inflammation.
“Our latest findings tell us, that the TL1A protein takes part in driving the inflammation, and therefore it makes sense to try and block the protein with biological medicines,” says Kirsten Reichwald, who hopes that her future research will help to provide even more specific knowledge about inflammation.
Kirsten Reichwald | EurekAlert!
Cancer: Molecularly shutting down cancer cachexia
30.08.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Bringing artificial enzymes closer to nature
30.08.2016 | Universität Basel
Scientists and engineers striving to create the next machine-age marvel--whether it be a more aerodynamic rocket, a faster race car, or a higher-efficiency jet...
Waveguides are widely used for filtering, confining, guiding, coupling or splitting beams of visible light. However, creating waveguides that could do the same for X-rays has posed tremendous challenges in fabrication, so they are still only in an early stage of development.
In the latest issue of Acta Crystallographica Section A: Foundations and Advances , Sarah Hoffmann-Urlaub and Tim Salditt report the fabrication and testing of...
Electrochemists at TU Graz have managed to use monocrystalline semiconductor silicon as an active storage electrode in lithium batteries. This enables an integrated power supply to be made for microchips with a rechargeable battery.
Small electrical gadgets, such as mobile phones, tablets or notebooks, are indispensable accompaniments of everyday life. Integrated circuits in the interiors...
Recent findings indicating the possible discovery of a previously unknown subatomic particle may be evidence of a fifth fundamental force of nature, according...
A nanocrystalline material that rapidly makes white light out of blue light has been developed by KAUST researchers.
25.08.2016 | Event News
24.08.2016 | Event News
12.08.2016 | Event News
30.08.2016 | Ecology, The Environment and Conservation
30.08.2016 | Power and Electrical Engineering
30.08.2016 | Life Sciences